<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-15-20-26</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5823</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФУНКЦИОНАЛЬНЫЕ ЗАБОЛЕВАНИЯ ЖКТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FUNCTIONAL GASTROINTESTINAL DISEASES</subject></subj-group></article-categories><title-group><article-title>Сочетанное течение ГЭРБ и функциональной диспепсии. Терапевтические возможности на клиническом примере</article-title><trans-title-group xml:lang="en"><trans-title>Differentiated approach to the choice of PPI in a patient with GERD in the practice of an outpatient (with a clinical case)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3125-6282</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пахомова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pakhomova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пахомова Инна Григорьевна, кандидат медицинских наук, доцент кафедры внутренних болезней</p><p>197341, Санкт-Петербург, ул. Аккуратова, д. 2 </p></bio><bio xml:lang="en"><p>Inna G. Pakhomova, Cand. of Sci. (Med.), Associate Professor of the Department of Internal Medicin</p><p>2, Akkuratova St., St Petersburg, 197341</p></bio><email xlink:type="simple">pakhomova-inna@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малко-Скрозь</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malko-Skroz</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малко-Скрозь Марина Владимировна, врач-гастроэнтеролог</p><p>197110, Санкт-Петербург, ул. Пионерская, д. 63 </p></bio><bio xml:lang="en"><p>Marina V. Malko-Skroz, Gastroenterologist</p><p>63 Pionerskaya St., St Petersburg, 197110</p></bio><email xlink:type="simple">marina-mskr@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр им. В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Клиника «Эксперт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Expert Clinic</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>10</month><year>2020</year></pub-date><volume>0</volume><issue>15</issue><fpage>20</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пахомова И.Г., Малко-Скрозь М.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Пахомова И.Г., Малко-Скрозь М.В.</copyright-holder><copyright-holder xml:lang="en">Pakhomova I.G., Malko-Skroz M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5823">https://www.med-sovet.pro/jour/article/view/5823</self-uri><abstract><p>В последние годы функциональные нарушения желудочно-кишечного тракта (ЖКТ) встречаются достаточно часто. Одним из значимых функциональных нарушений является функциональная диспепсия (ФД), которая широко распространена в популяции. Кроме того, в клинической практике врачей амбулаторного звена возросла доля сочетанных вариантов или перекреста нескольких видов функциональных нарушений, или сочетание функциональных нарушений с органической патологией. Так, по данным систематических обзоров, сочетанное течение гастроэзофагеальной рефлюксной болезни (ГЭРБ) и ФД встречается как минимум у трети пациентов. При этом сочетанная функциональная патология ЖКТ изменяет клиническую картину ГЭРБ, что затрудняет дифференциальную диагностику, приводит к неадекватному и множественному назначению лекарственных препаратов и, нередко, низкой эффективности назначенной терапии. Все это отрицательно влияет на качество жизни больных. Тактика ведения пациентов с сочетанным течением ГЭРБ и ФД порой представляет определенные трудности, поскольку нет доступных рекомендаций по патогенетической терапии и профилактическим мероприятиям. На сегодняшний день изучены и описаны возможные звенья патогенеза как ГЭРБ, так и ФД, которые предопределяют те или иные подходы к лечению различных вариантов этих двух заболеваний. Медикаментозная терапия ГЭРБ включает назначение ингибиторов протонной помпы (ИПП), антирефлюксных препаратов. В терапии ФД эффективны прокинетики и/или ИПП. Рациональным подходом к терапии перекреста ГЭРБ и ФД является назначение препарата с двойным механизмом действия, имеющего в своем составе как прокинетик, так и ИПП. Примером такого подхода является назначение омепразола и домперидона. Применение данной комбинации представлено в клиническом случае.</p></abstract><trans-abstract xml:lang="en"><p>In recent years, functional disorders of the gastrointestinal tract (GIT) are quite common. The most significant functional disorders are functional dyspepsia (FD), which is widespread in the population. In addition, in the clinical practice of outpatient doctors, the proportion of combined variants or overlap of several types of functional disorders or a combination of functional disorders with organic pathology has increased. So, according to systematic reviews, the combined course of gastroesophageal reflux disease (GERD) and FD occurs in at least one third of patients. At the same time, the combined functional pathology of the gastrointestinal tract changes the clinical picture of GERD, which complicates differential diagnosis, leads to inadequate and multiple prescription of drugs and often low effectiveness of the prescribed therapy. All this negatively affects the quality of life of patients. The tactics of managing patients with the combined course of GERD and FD sometimes presents certain difficulties, since there are no available recommendations for pathogenetic therapy and preventive measures. To date, possible links in the pathogenesis of both GERD and FD have been studied and described, which predetermine certain approaches to the treatment of various variants of these two diseases. Drug therapy for GERD includes the appointment of proton pump inhibitors (PPIs), antireflux drugs. In FD therapy, prokinetics and/or PPIs are effective. A rational approach in the treatment of the intersection of GERD and FD is the appointment of a drug with a dual mechanism of action, which contains both a prokinetic and a PPI. An example of this approach is the appointment of omeprazole and domperidone. The use of this drug is presented in a clinical case.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гастроэзофагеальная рефлюксная болезнь</kwd><kwd>функциональная диспепсия</kwd><kwd>синдром перекреста</kwd><kwd>омепразол</kwd><kwd>домперидон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gastroesophageal reflux disease</kwd><kwd>functional dyspepsia</kwd><kwd>intersection syndrome</kwd><kwd>omeprazole</kwd><kwd>domperidone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Пасечников В.Д., Голубь И.В. Синдром перекреста гастроэзофагеальной рефлюксной болезни и функциональной диспепсии: распространенность, факторы риска и предикторы развития. Клинические перспективы гастроэнтерологии, гепатологии. 2014;(6):3–10. Режим доступа: https://elibrary.ru/item.asp?id=22620217.</mixed-citation><mixed-citation xml:lang="en">Pasechnikov V.D., Golub I.V. Gastroesophageal reflux disease and functional  dyspepsia overlap syndrome: prevalence, risk factors and andoesoph. Klinicheskie perspektivy gastroenterologii, gepatologii = Clinical prospekts of gastroenterology, gepatology. 2014;(6):3–10. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22620217.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kitapçioğlu G., Mandiracioğlu A., Caymaz Bor C., Bor S. Overlap of symptoms of dyspepsia and gastroesophageal reflux in the community. Turk J Gastroenterol. 2007;18(1):14–19. Available at: https://www.turkjgastroenterol.org/en/overlap-of-symptoms-of-dyspepsia-and-gastroesophageal-reflux-in-the-community-133508.</mixed-citation><mixed-citation xml:lang="en">Kitapçioğlu G., Mandiracioğlu A., Caymaz Bor C., Bor S. Overlap of symptoms of dyspepsia and gastroesophageal reflux in the community. Turk J Gastroenterol. 2007;18(1):14–19. Available at: https://www.turkjgastroenterol.org/en/overlap-of-symptoms-of-dyspepsia-and-gastroesophageal-reflux-in-the-community-133508.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S.Y., Lee K.J., Kim S.J., Cho S.W. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. doi: 10.1159/000211715.</mixed-citation><mixed-citation xml:lang="en">Lee S.Y., Lee K.J., Kim S.J., Cho S.W. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009;79(3):196–201. doi: 10.1159/000211715.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yarandi S.S., Nasseri-Moghaddam S., Mostajabi P., Malekzadeh R. Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J Gastroenterol. 2010;16(10):1232– 1238. doi: 10.3748/wjg.v16.i9.1232.</mixed-citation><mixed-citation xml:lang="en">Yarandi S.S., Nasseri-Moghaddam S., Mostajabi P., Malekzadeh R. Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J Gastroenterol. 2010;16(10):1232–1238. doi: 10.3748/wjg.v16.i9.1232.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16(2):148–156. doi: 10.5056/jnm.2010.16.2.148.</mixed-citation><mixed-citation xml:lang="en">Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16(2):148–156. doi: 10.5056/jnm.2010.16.2.148.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ghoshal U.C., Singh R., Chang F.Y., Hou X., Wong B.C., Kachintorn U. Epidemiology of Uninvestigated and Functional Dyspepsia in Asia: Facts and Fiction. J Neurogastroenterol Motil. 2011;17(3);235–244. doi: 10.5056/jnm.2011.17.3.235.</mixed-citation><mixed-citation xml:lang="en">Ghoshal U.C., Singh R., Chang F.Y., Hou X., Wong B.C., Kachintorn U. Epidemiology of Uninvestigated and Functional Dyspepsia in Asia: Facts and Fiction. J Neurogastroenterol Motil. 2011;17(3);235–244. doi: 10.5056/jnm.2011.17.3.235.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wu H.C., Tuo B.G., Wu W.M., Gao Y., Xu Q.Q., Zhao K. Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex, and Helicobacter pylori infection. Dig Dis Sci. 2008;53(10):2650–2656. doi: 10.1007/s10620-007-0177-7.</mixed-citation><mixed-citation xml:lang="en">Wu H.C., Tuo B.G., Wu W.M., Gao Y., Xu Q.Q., Zhao K. Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex, and Helicobacter pylori infection. Dig Dis Sci. 2008;53(10):2650–2656. doi: 10.1007/s10620-007-0177-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. doi: 10.1136/gutjnl-2012-304269.</mixed-citation><mixed-citation xml:lang="en">El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. doi: 10.1136/gutjnl-2012-304269.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Исаков В.А., Морозов С.В., Ставраки Е.С., Комаров Р.М. Анализ Распространенности Изжоги: национальное эпидемиологическое исследование взрослого городского населения (АРИАДНА). Экспериментальная и клиническая гастроэнтерология. 2008;(1):20–30. Режим доступа: https://elibrary.ru/item.asp?id=15238225.</mixed-citation><mixed-citation xml:lang="en">Isakov V.A., Morozov S.V., Stavraki E.S., Komarov R.M. Distribution Analysis of Heartburn: National Epidemiological Study of Adult Urban Population (ARIADNA). Ehksperimentalnaya i klinicheskaya gastroehnterologiya = Experimental and Clinical Gastroenterology. 2008;(1):20–30. (In Russ.) Available at: https://elibrary.ru/item.asp?id=15238225.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Машарова А.А., Бордин Д.С., Васильев Ю.В., Ткаченко Е.И., Абдулхаков Р.А. и др. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» (МЭГРЕ): первые итоги. Экспериментальная и клиническая гастроэнтерология. 2009;(6):4–12. Режим доступа: https://elibrary.ru/item.asp?id=15234959.</mixed-citation><mixed-citation xml:lang="en">Lazebnik L.B., Masharova A.A., Bordin D.S., Vasilyev Yu.V., Tkachenko E.I., Abdulkhakov R.A. et al. Multi-center study “Epidemiology of Gastroesophageal Reflux Disease in Russia” (MEGRE): first results. Ehksperimentalnaya i klinicheskaya gastroehnterologiya = Experimental and Clinical Gastroenterology. 2009;(6):4–12. (In Russ.). Available at: https://elibrary.ru/item.asp?id=15234959.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">De Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastro-esophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787–5797. doi: 10.3748/wjg.v19.i35.5787.</mixed-citation><mixed-citation xml:lang="en">De Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastro-esophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787–5797. doi: 10.3748/wjg.v19.i35.5787.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kaji M., Fujiwara Y., Shiba M., Kohata Y., Yamagami H., Tanigawa T. et al. Prevalence of overlaps between GERD, FD and IBS and impact on healthrelated quality of life. J Gastroenterol Hepatol. 2010;25(6):1151–1156. doi: 10.1111/j.1440-1746.2010.06249.x.</mixed-citation><mixed-citation xml:lang="en">Kaji M., Fujiwara Y., Shiba M., Kohata Y., Yamagami H., Tanigawa T. et al. Prevalence of overlaps between GERD, FD and IBS and impact on healthrelated quality of life. J Gastroenterol Hepatol. 2010;25(6):1151–1156. doi: 10.1111/j.1440-1746.2010.06249.x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dent J. Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy. J Neurogastroenterol Motil. 2008;20(Suppl 1):91–102. doi: 10.1111/j.1365-2982.2008.01096.x.</mixed-citation><mixed-citation xml:lang="en">Dent J. Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy. J Neurogastroenterol Motil. 2008;20(Suppl 1):91–102. doi: 10.1111/j.1365-2982.2008.01096.x.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Бордин Д.С. «Кислотный карман» как патогенетическая основа и терапевтическая мишень при гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2014;86(2):76–81. Режим доступа: https://elibrary.ru/item.asp?id=21369875.</mixed-citation><mixed-citation xml:lang="en">Bordin D.S. The Acid Pocket as the Pathogenic Basis and Therapeutic Target in Gastroesophageal Reflux Disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2014;86(2):76–81. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21369875.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sarnelli G., Caenepeel P., Geypens B., Janssens J., Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98(4):783–788. doi: 10.1111/j.1572-0241.2003.07389.x.</mixed-citation><mixed-citation xml:lang="en">Sarnelli G., Caenepeel P., Geypens B., Janssens J., Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98(4):783–788. doi: 10.1111/j.1572-0241.2003.07389.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Camilleri C.E., Carlson P.J., Camilleri M., Castillo E.J., Locke G.R. 3rd, Geno D.M. et al. A study of candidate genotypes associated with dyspepsia in a U.S. community. American Journal of Gastroenterology. 2006;101(3):581–592. doi: 10.1111/j.1572-0241.2006.00481.x.</mixed-citation><mixed-citation xml:lang="en">Camilleri C.E., Carlson P.J., Camilleri M., Castillo E.J., Locke G.R. 3rd, Geno D.M. et al. A study of candidate genotypes associated with dyspepsia in a U.S. community. American Journal of Gastroenterology. 2006;101(3):581–592. doi: 10.1111/j.1572-0241.2006.00481.x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Corsetti M., Caenepeel P., Fischler B., Janssens J., Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004;99(6):1152–1159. Available at: https://journals.lww.com/ajg/Abstract/2004/06000/Impact_of_Coexisting_Irritable_Bowel_Syndrome_on.32.aspx.</mixed-citation><mixed-citation xml:lang="en">Corsetti M., Caenepeel P., Fischler B., Janssens J., Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004;99(6):1152–1159. Available at: https://journals.lww.com/ajg/Abstract/2004/06000/Impact_of_Coexisting_Irritable_Bowel_Syndrome_on.32.aspx.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Y., Wilder-Smith C.H., Li X.H., Wong R.K.M., Hammer J., Ho K.Y. Characterization of a reproducible gastric pain model using oral capsaicin titration in healthy volunteers. Neurogastroenterology and Motility. 2011;23(7):261–270. doi: 10.1111/j.1365-2982.2011.01734.x.</mixed-citation><mixed-citation xml:lang="en">Cao Y., Wilder-Smith C.H., Li X.H., Wong R.K.M., Hammer J., Ho K.Y. Characterization of a reproducible gastric pain model using oral capsaicin titration in healthy volunteers. Neurogastroenterology and Motility. 2011;23(7):261–270. doi: 10.1111/j.1365-2982.2011.01734.x.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki H., Matsuzaki J., Hibi T. Ghrelin and oxidative stress in gastrointestinal tract. J Clin Biochem Nutr. 2011;48(2):122–125. doi: 10.3164/jcbn.10-16GFR.</mixed-citation><mixed-citation xml:lang="en">Suzuki H., Matsuzaki J., Hibi T. Ghrelin and oxidative stress in gastrointestinal tract. J Clin Biochem Nutr. 2011;48(2):122–125. doi: 10.3164/jcbn.10-16GFR.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chojnacki C., Poplawski T., Klupinska G., Blasiak J., Chojnacki J., Reiter R.J. Secretion of melatonin and 6-sulfatoxymelatonin urinary excretion in functional dyspepsia. World J Gastroenterol. 2011;17(21):2646–2651. doi: 10.3748/wjg.v17.i21.2646.</mixed-citation><mixed-citation xml:lang="en">Chojnacki C., Poplawski T., Klupinska G., Blasiak J., Chojnacki J., Reiter R.J. Secretion of melatonin and 6-sulfatoxymelatonin urinary excretion in functional dyspepsia. World J Gastroenterol. 2011;17(21):2646–2651. doi: 10.3748/wjg.v17.i21.2646.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150(6):1262–1279. doi: 10.1053/j.gastro.2016.02.032.</mixed-citation><mixed-citation xml:lang="en">Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150(6):1262–1279. doi: 10.1053/j.gastro.2016.02.032.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Дичева Д.Т., Щегланова М.П., Андреев Д.Н., Заборовский А.В. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016 г.). Гастроэнтерология. Приложение к журналу Consilium Medicum. 2016;(2):5–10. Режим доступа: https://elibrary.ru/item.asp?id=28147422.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Dicheva D.T., Shcheglanova M.P., Andreev D.N., Zaborovskiy A.V. Functional dyspepsia in the context of the 2016 Rome IV updates. Gastroehnterologiya. Prilozhenie k zhurnalu Consilium Medicum = Gastroenterology. Appendix to the Journal Consilium Medicum. 2016;(2):5–10. (In Russ.) Available at: https://elibrary.ru/item.asp?id=28147422.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki H., Masaoka T., Sakai G., Ishii H., Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol. 2005;20(11):1652–1660. doi: 10.1111/j.1440-1746.2005.04039.x.</mixed-citation><mixed-citation xml:lang="en">Suzuki H., Masaoka T., Sakai G., Ishii H., Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol. 2005;20(11):1652–1660. doi: 10.1111/j.1440-1746.2005.04039.x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gwee K.A., Teng L., Wong R.K., Ho K.Y., Sutedja D.S., Yeoh K.G. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2009;21(4):417–424. doi: 10.1097/MEG.0b013e328317b89e.</mixed-citation><mixed-citation xml:lang="en">Gwee K.A., Teng L., Wong R.K., Ho K.Y., Sutedja D.S., Yeoh K.G. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2009;21(4):417–424. doi: 10.1097/MEG.0b013e328317b89e.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Miwa H., Watari J., Fukui H., Oshima T., Tomita T., Sakurai J. et al. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol. 2011;26(Suppl 3):53–60. doi: 10.1111/j.1440-1746.2011.06633.x.</mixed-citation><mixed-citation xml:lang="en">Miwa H., Watari J., Fukui H., Oshima T., Tomita T., Sakurai J. et al. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol. 2011;26(Suppl 3):53–60. doi: 10.1111/j.1440-1746.2011.06633.x.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маев И.В., Шептулин А.А., Лапина Т.Л., Трухманов А.С., Картавенко И.М. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):50–61. doi: 10.22416/1382-4376-2017-27-1-50-61.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M. et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.) doi: 10.22416/1382-4376-2017-27-1-50-61.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. doi: 10.1002/14651858.CD001960.pub3.</mixed-citation><mixed-citation xml:lang="en">Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. doi: 10.1002/14651858.CD001960.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Дичева Д.Т., Андреев Д.Н., Ульянкина Е.В. Синдром перекреста ГЭРБ, функциональной диспепсии и СРК: патогенетические связи и подходы к терапии. Эффективная фармакотерапия. 2019;15(36):64–70. doi: 10.33978/2307-3586-2019-15-36-64-70.</mixed-citation><mixed-citation xml:lang="en">Dicheva D.T., Andreyev D.N., Ulyankina Ye.V. Intersection Syndrome of Gastroesophageal Reflux Disease, Functional Dyspepsia and Irritable Bowel Syndrome: Pathogenetic Links and Approaches to Therapy. Ehffektivnaya farmakoterapiya = Effective pharmacotherapy. 2019;15(36):64–70. (In Russ.) doi: 10.33978/2307-3586-2019-15-36-64-70.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Dabоul I., Taleb N., Alkheshen M., Abell T.L. Domperidone decreases the average daily insulin requirement in patients with diabetic gastropathy. Neurogastroenterol Motil. 2000;12:480.</mixed-citation><mixed-citation xml:lang="en">Dabоul I., Taleb N., Alkheshen M., Abell T.L. Domperidone decreases the average daily insulin requirement in patients with diabetic gastropathy. Neurogastroenterol Motil. 2000;12:480.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Van Roeden S.E., Belle-van Meerkerk G., van Tuyl S.A., van de Ree M.A., Muller A.F. Domperidone and the risk of sudden cardiac death. Ned Tijdschr Geneeskd. 2013;157(45):A6770. Available at: https://pubmed.ncbi.nlm.nih.gov/24191928.</mixed-citation><mixed-citation xml:lang="en">Van Roeden S.E., Belle-van Meerkerk G., van Tuyl S.A., van de Ree M.A., Muller A.F. Domperidone and the risk of sudden cardiac death. Ned Tijdschr Geneeskd. 2013;157(45):A6770. Available at: https://pubmed.ncbi.nlm.nih.gov/24191928.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz A., Cooper C.J., Alvarez A., Gomez Y., Sarosiek I., McCallum R.W. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421– 424. doi: 10.1097/MAJ.0000000000000439.</mixed-citation><mixed-citation xml:lang="en">Ortiz A., Cooper C.J., Alvarez A., Gomez Y., Sarosiek I., McCallum R.W. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421– 424. doi: 10.1097/MAJ.0000000000000439.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Coloma P.M., Schuemie M.J., Trifirò G., Furlong L., van Mulligen E., Bauer-Mehren A. et al. Drug-induced acute myocardial infarction: identifying ‘prime suspects’ from electronic healthcare records-based surveillance system. PLoS ONE. 2013;8(8):e72148. doi: 10.1371/journal.pone.0072148.</mixed-citation><mixed-citation xml:lang="en">Coloma P.M., Schuemie M.J., Trifirò G., Furlong L., van Mulligen E., BauerMehren A. et al. Drug-induced acute myocardial infarction: identifying ‘prime suspects’ from electronic healthcare records-based surveillance system. PLoS ONE. 2013;8(8):e72148. doi: 10.1371/journal.pone.0072148.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Лялюкова Е.А., Батищева Г.А., Визе-Хрипунова М.А., Лапина Е.Д., Лялюкова А.С., Онучина Е.В. и др. Синдром диспепсии в первичном звене здравоохранения: клинические варианты, тактика ведения пациентов. Трудный пациент. 2019;17(6–7):38–46. doi: 10.24411/2074-1995-2019-10051.</mixed-citation><mixed-citation xml:lang="en">Lyalyukova E.A., Batishcheva G.A., Vise-Khripunova M.A., Lapina E.D., Lyalyukova A.S., Onuchina E.V. et al. Dyspepsia Syndrome in Primary Health Care: Clinical Options, Patient Management Tactics. Trudnyy patsient = Difficult Patient. 2019;17(6–7):38–46. (In Russ.) doi: 10.24411/2074-1995-2019-10051.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
